MAIA · Maia Biotechnology, Inc. - Financials
Annual line items from SEC XBRL filings, sourced from EDGAR's Company Facts API with fallback to the quarterly Financial Statement Data Sets. See issuer overview for Form 4 activity and 10-K signals.
Income Statement
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|
| Revenue | - | $0 | $0 | $0 |
| Cost of Revenue | - | - | - | - |
| Gross Profit | - | - | - | - |
| R&D | $453.7K | $10.01M | $11.11M | $3.50M |
| SG&A | $9.72M | $6.95M | $9.07M | $6.14M |
| Total Operating Expenses | $24.27M | $16.96M | $20.18M | $16.18M |
| D&A | - | - | - | - |
| Operating Income | ($24.27M) | ($16.96M) | ($20.18M) | ($16.18M) |
| Interest Expense | - | $57 | $6.9K | $827.5K |
| Income Tax | $2.0K | - | - | - |
| Net Income | ($23.25M) | ($23.25M) | ($19.77M) | ($16.22M) |
| EPS - Basic | ($0.70) | ($1.05) | ($1.49) | ($2.37) |
| EPS - Diluted | ($0.70) | ($1.05) | ($1.49) | ($2.37) |
Balance Sheet
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|
| Cash & Equivalents | $0 | $0 | $0 | $0 |
| Accounts Receivable | - | - | - | - |
| Inventory | - | - | - | - |
| Accounts Payable | $2.04M | $1.51M | $1.64M | $1.17M |
| Current Assets | $9.70M | $10.15M | $7.56M | $11.81M |
| Total Assets | $9.70M | $10.16M | $7.57M | $12.02M |
| Current Liabilities | $5.84M | $3.83M | $4.94M | $3.27M |
| Long-term Debt | - | - | - | - |
| Total Liabilities | $7.33M | $6.52M | $7.09M | $3.51M |
| Stockholders' Equity | $2.38M | $3.63M | $477.5K | $8.51M |
| Retained Earnings | ($109.63M) | ($87.23M) | ($63.98M) | ($44.21M) |
Cash Flow
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|
| Operating Cash Flow | ($18.84M) | ($15.70M) | ($13.07M) | ($4.12M) |
| Investing Cash Flow | - | - | - | - |
| Financing Cash Flow | $17.91M | $18.18M | $9.27M | $14.03M |
| CapEx | - | - | - | - |
| Free Cash Flow | - | - | - | - |
Ratios
| Metric | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|
| Profitability | ||||
| Gross margin | - | - | - | - |
| Operating margin | - | - | - | - |
| EBITDA margin | - | - | - | - |
| Net margin | - | - | - | - |
| Free cash flow margin | - | - | - | - |
| FCF / Net income | - | - | - | - |
| R&D / Revenue | - | - | - | - |
| SG&A / Revenue | - | - | - | - |
| Effective tax rate | - | - | - | - |
| Return on assets | -239.6% | -229.0% | -261.3% | -134.9% |
| Return on equity | -978.8% | -639.8% | -4140.8% | -190.6% |
| Return on invested capital | - | - | - | - |
| Liquidity | ||||
| Current ratio | 1.66 | 2.65 | 1.53 | 3.61 |
| Quick ratio | 1.66 | 2.65 | 1.53 | 3.61 |
| Cash ratio | 0.00 | 0.00 | 0.00 | 0.00 |
| Leverage | ||||
| Debt / Equity | - | - | - | - |
| Debt / Assets | - | - | - | - |
| Debt / EBITDA | - | - | - | - |
| Interest coverage | - | -297494.9x | -2940.8x | -19.5x |
| Equity multiplier | 4.08 | 2.79 | 15.85 | 1.41 |
| Liabilities / Assets | 0.76 | 0.64 | 0.94 | 0.29 |
| Efficiency | ||||
| Asset turnover | - | 0.00 | 0.00 | 0.00 |
| Inventory turnover | - | - | - | - |
| Days sales outstanding | - | - | - | - |
| Days inventory outstanding | - | - | - | - |
| Days payable outstanding | - | - | - | - |
| Cash conversion cycle | - | - | - | - |
| Valuation | ||||
| P / E | - | - | - | - |
| P / B | 20.7x | 12.1x | 32.5x | 2.2x |
| P / S | - | - | - | - |
| EV / EBITDA | - | - | - | - |
| Growth | ||||
| Revenue growth (YoY) | - | - | - | - |
| Revenue CAGR (3y) | - | - | - | - |
| Revenue CAGR (5y) | - | - | - | - |
| Gross profit growth (YoY) | - | - | - | - |
| Operating income growth (YoY) | -43.1% | 16.0% | -24.8% | - |
| Net income growth (YoY) | 0.0% | -17.6% | -21.9% | - |
| EPS growth (YoY) | 33.3% | 29.5% | 37.1% | - |
| EPS CAGR (3y) | - | - | - | - |
| EPS CAGR (5y) | - | - | - | - |
| FCF growth (YoY) | - | - | - | - |
| FCF CAGR (5y) | - | - | - | - |
| Book value growth (YoY) | -34.6% | 661.2% | -94.4% | - |
Stability scores
Piotroski F-score
FY 2025 · 9-point quality
1/9
Weak
- ✗Net income positive
- ✗Operating cash flow positive
- ✗ROA improved YoY
- ✓Cash flow > net income
- -Long-term debt decreased
- ✗Current ratio improved
- ✗No share dilution
- -Gross margin improved
- -Asset turnover improved
Peer comparison
Same SIC group: Pharmaceutical Preparations
Comparing MAIA Biotechnology against the 5 most active filers in the same SIC group.